Boehringer's Respimat nabs FDA approval for COPD; Pacira shares drop on FDA promo warning;

@FiercePharma: Judge tosses RICO claims over AbbVie's Humira, AndroGel copay cards: | Follow @FiercePharma

@EricPFierce: ICYMI: Mylan proposes plan to avoid nitroglycerin shortage in Canada. Story | Follow @EricPFierce

> Boehringer Ingelheim said its inhaled drug for chronic obstructive pulmonary disease, Spiriva Respimat, won approval from the FDA, with a launch expected in January. Release

> The FDA slapped Pacira Pharmaceuticals ($PCRX) for overstating the benefits of its pain drug Exparel, calling the claims "misleading." Report

> Actavis ($ACT) said Purdue Pharma sued it for patent infringement after it asked the FDA to approve generic versions of Purdue's buprenorphine patch, Butrans. Report

> Indian business leaders challenged the American Enterprise Institute, a conservative think tank, for what they called a "smear campaign" against its pharma industry. Release

> GlaxoSmithKline ($GSK) won approval from local planning officials for its new biopharma facility in Ulverston, U.K., which is expected to create 700-plus jobs. Report

> Rabies experts unveiled a plan to eliminate the disease via mass dog vaccinations in certain regions. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: HealthKit pulled from iPhone 6 after update crashes customers' phones. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. Story | Follow @VarunSaxena2

@EmilyWFierce: FDA OKs "tumor paint" made from scorpion venom for Phase I clinical trial. Article | Follow @EmilyWFierce

> DOD awards $67M in contracts to Zoll, Philips. Item

> Researchers develop noninvasive device to monitor brain blood flow. Story

> Former AdvaMed board chairman, eye care company CEO accused of insider trading. Article

Biotech News

@FierceBiotech: Biosimilars outfit Coherus pitches an $86M IPO, targeting Enbrel and Humira. More | Follow @FierceBiotech

@JohnCFierce: FierceBiotech's 2014 Fierce 15 - Still trending, all week long. Ain't it cool? Report | Follow @JohnCFierce

@DamianFierce: Tomorrow is FDA decision date No. 4 for $ALIM and $PSDV's Iluvien, if you're into that sort of thing. Both trading up at the moment. | Follow @DamianFierce

@EmilyMFierce: How is it that only one person has been cured of #HIV? A new monkey study reveals clues. Story | Follow @EmilyMFierce

> GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board. Chutes & Ladders

> Takeda pours $25M into biotech dealmaker BioMotiv. News

> Gilead nears EU approval for the next big thing in hep C. More

And Finally... An outbreak of enterovirus respiratory infections in the Midwest is spreading, baffling scientists. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.